<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527863</url>
  </required_header>
  <id_info>
    <org_study_id>SAFA-2-2014</org_study_id>
    <secondary_id>2014-001973-15</secondary_id>
    <nct_id>NCT02527863</nct_id>
  </id_info>
  <brief_title>Effect of the Aquaretic Tolvaptan on Nitric Oxide System</brief_title>
  <acronym>TOPO</acronym>
  <official_title>The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Central Hemodynamics During Baseline Conditions and After Inhibition of the Nitric Oxide System in Patients With Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and
      sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which
      stimulates V1-receptors in the vascular bed and may change both central and brachial
      hemodynamics and plasma concentration of vasoactive hormones.

      The purpose of the study is to measure the effects of tolvaptan on renal handling of water
      and sodium, systemic hemodynamics and vasoactive hormones at baseline and during nitric oxide
      (NO)-inhibition with L-NG-monomethyl-arginine (L-NMMA) in patients with autosomal dominant
      polycystic kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CH2O (Measurement of H2O clearance)</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of H2O clearance at baseline, during and after L-NMMA infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine biomarkers(Aquaporins and Epithelial Sodium Channels Î³)</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central and brachial blood pressure</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive Hormones( Angiotensin II, Aldosterone, Endothelin, Atrial Natriuretic Peptide, Brain Natriuretic Peptide, Arginin Vasopressin)</measure>
    <time_frame>5-6 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional sodium excretion</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of Sodium excretion at baseline, during and after L-NMMA infusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>60 mg Tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of 60 mg tolvaptan on each examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of a Unikalk tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>60 mg Tolvaptan pr day for 1 day</description>
    <arm_group_label>60 mg Tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet Unikalk pr day for 1 day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Unikalk</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Caucasian men and women

          2. Age between 18-65 years

          3. ADPKD, diagnosed by genetic testing of PKD1 (&gt;85%) or PKD2 mutations, or by
             ultrasonography:

               1. patients with negative family history for ADKPD and more than 10 cysts in each
                  kidney and no extrarenal or renal findings that suggest causes to cyst formation.

               2. patients with positive family history for ADPKD:

                    -  15-39 yr of age and at least 3 or more unilateral or bilateral.

                    -  40-59 yr of age and 2 or more cysts in each kidney.

                    -  60 yr of age and at least 4 cysts in each kidney.

          4. Kidney function corresponding to CKD stages 1-3(eGFR&gt; 30 mL/min/1,73 m2),

          5. BMI between 18.5 and 35.5 kg/m2.

        Exclusion Criteria:

          1. Clinical signs of diseases in the heart, lungs, endocrine organs, brain or neoplastic
             disease,

          2. clinically significant abnormalities in blood or urine sample at the inclusion

          3. previous cerebrovascular insults,

          4. previous clinical evidence for aneurysm

          5. Alcohol or drug abuse,

          6. smoking,

          7. pregnancy or breastfeeding,

          8. clinically significant changes in the electrocardiogram,

          9. medication except antihypertensive agents and oral contraceptives,

         10. blood pressure&gt;170/105 mmHg despite treatment with metoprolol and/or amlodipine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erling B Pedersen</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medical Research and Medicine, Holstebro Regional Hospital Holstebro, Holstebro, Denmark, 7500</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medical Research and Medicine, Holstebro Regional Hospital</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Professor, MD, Dr.Sci.</investigator_title>
  </responsible_party>
  <keyword>Tolvaptan</keyword>
  <keyword>L-NMMA</keyword>
  <keyword>ADPKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

